

GUFIC BIOSCIENCES LIMITED					
Regd. Office : 37, Kamala Bhavan II, S. Nityanand Road, Andheri (East), Mumbai - 400069 (CIN- L24100MH1984PLC033519) Website - www.gufic.com, email - corporaterelations@guficbio.com, Ph-022 67261000, Fax - 022 67261068					
(Rs. in Lakhs except EPS)					
Statement of Un-Audited Financial Results for the Quarter Ended June 30, 2023					
Sr. No.	Particulars	Quarter Ended			Year ended
		30-Jun-23	30-Jun-22	31-Mar-23	31-Mar-23
		Unaudited	Unaudited	Audited	Audited
1	Income				
a	Revenue from operations	19,502.02	16,527.63	17,303.58	69,062.08
b	Other income	88.12	37.47	62.34	257.39
	<b>Total Income</b>	<b>19,590.14</b>	<b>16,565.10</b>	<b>17,365.92</b>	<b>69,319.47</b>
2	Expenses				
a	Cost of materials consumed	8,038.31	6,311.38	8,355.42	33,936.27
b	Purchase of stock-in-trade	1,606.24	677.05	966.33	2,584.38
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	39.44	764.73	(1,065.42)	(3,338.61)
d	Employee benefits expense	2,337.30	2,142.73	2,192.77	8,673.18
e	Finance cost	407.27	90.83	292.18	822.33
f	Depreciation and amortisation expense	423.63	436.50	591.82	2,228.10
g	Other expenses	3,933.04	3,313.85	3,639.59	13,741.73
	<b>Total Expenses</b>	<b>16,785.23</b>	<b>13,737.07</b>	<b>14,972.69</b>	<b>58,647.38</b>
3	Total Profit before exceptional items and tax (1-2)	2,804.91	2,828.03	2,393.23	10,672.09
4	Exceptional items	-	-	-	-
5	<b>Total Profit Before Tax</b>	<b>2,804.91</b>	<b>2,828.03</b>	<b>2,393.23</b>	<b>10,672.09</b>
6	Tax Expense				
	Current tax	650.00	736.00	620.00	2,821.00
	Deferred tax	92.62	(13.12)	(37.33)	(119.39)
	<b>Total Tax Expenses</b>	<b>742.62</b>	<b>722.88</b>	<b>582.67</b>	<b>2,701.61</b>
7	<b>Net Profit for the period from continuing operations</b>	<b>2,062.29</b>	<b>2,105.15</b>	<b>1,810.56</b>	<b>7,970.48</b>
8	<b>Total Profit for Period</b>	<b>2,062.29</b>	<b>2,105.15</b>	<b>1,810.56</b>	<b>7,970.48</b>
9	Other Comprehensive Income (OCI)				
	Items that will not be reclassified to Profit/(Loss)	-	-	(0.71)	(0.71)
	Less: Income tax relating to items that will not be reclassified to Profit/(Loss)	-	-	0.18	0.18
	Other Comprehensive Income/(Loss) (net of taxes)	-	-	(0.53)	(0.53)
10	<b>Total Comprehensive Income</b>	<b>2,062.29</b>	<b>2,105.15</b>	<b>1,810.03</b>	<b>7,969.95</b>
11	<b>Reserves</b>				<b>33,811.37</b>
12	Details of Equity Share Capital				
	Paid-up equity share capital	969.45	969.45	969.45	969.45
	Face Value of equity share capital (Rs.)	1.00	1.00	1.00	1.00
13	Earning per equity share				
i	Basic earnings per share from continuing and discontinued operations	2.13	2.17	1.87	8.22
ii	Diluted earnings per share from continuing and discontinued operations	2.13	2.17	1.87	8.22


**Notes:**

- The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards), Rules, 2015 (Ind AS) as amended, prescribed under section 133 of Companies Act, 2013, read with rules issued thereunder.
- The above results for the quarter ended June 30, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 11, 2023. The Statutory Auditors have carried out review of the results for quarter ended June 30, 2023.
- The Company's business activity falls within a single operating segment i.e. Pharmaceuticals.
- The Company have incorporated Gufic UK Limited ("GUL") in the United Kingdom and Gufic Ireland Limited ("GIL") in Ireland on March 15, 2022 and March 02, 2023, respectively, with the intent of making both the said Companies as its Wholly Owned Subsidiaries. However, the Company have not made any investment in GUL and GIL towards its shares subscription till the quarter ended June 30, 2023. Further GUL and GIL have not yet commenced its business operations till June 30, 2023. Thus the Company is not required to prepare Consolidated Financial Results for the quarter ended June 30, 2023.
- The figures for the quarter ended March 31, 2023 are balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter ended December 31, 2022 which were subjected to limited review.
- Previous year/quarters figures have been regrouped/reclassified, wherever necessary.

FOR GUFIC BIOSCIENCES LIMITED

  
JAYESH P. CHOKSI  
CHAIRMAN & MANAGING DIRECTOR  
DIN : 00001729

PLACE : MUMBAI  
DATE : 11/08/2023



*only for Indentification  
purpose.*





# MITTAL AGARWAL & COMPANY

## CHARTERED ACCOUNTANTS

Limited Review Report on the Unaudited Quarterly Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended

Review Report to  
The Board of Directors  
Gufic Biosciences Limited

- 1) We have reviewed the accompanying statement of Unaudited Financial Results of **Gufic Biosciences Limited** (the "Company") for the quarter ended 30 June 2023 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2) This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
- 3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit, and accordingly, we do not express an audit opinion.
- 4) Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.



For Mittal Agarwal & Company  
Chartered Accountants  
(Firm Registration No. 131025W)

  
Piyush Agarwal  
Partner

Membership No. 135505

Place: Mumbai  
Dated: 11/08/2023

UDIN: 23135505BQXCVB3329